| Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant M Rohrschneider, S Bhagwat, R Krampe, V Michler, J Breitkreutz, ... Molecular pharmaceutics 12 (8), 2618-2624, 2015 | 88 | 2015 |
| Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers S Bhagwat, U Schilling, MJ Chen, X Wei, R Delvadia, M Absar, B Saluja, ... Pharmaceutical research 34, 2541-2556, 2017 | 53 | 2017 |
| Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches E Amini, A Kurumaddali, S Bhagwat, SM Berger, G Hochhaus Pharmaceutics 13 (8), 1109, 2021 | 10 | 2021 |
| Development of an in vitro test method for dissolution of inhaled corticosteroids S Bhagwat, M Rohrschneider, S Alfadehl, G Hochhaus JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY 26 (2), A58-A59, 2013 | 5 | 2013 |
| Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study ML Brantly, BT Kuhn, HW Farah, R Mahadeva, A Cole, CL Chang, ... Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 11 (3 …, 2024 | 2 | 2024 |
| Mechanistic pharmacokinetic/pharmacodynamic modeling in support of a patient-convenient, longer dosing interval for carfilzomib, a covalent inhibitor of the proteasome MR Yago, K Mehta, M Bose, S Bhagwat, VS Chopra, S Dutta, VV Upreti Clinical Pharmacokinetics 62 (5), 779-788, 2023 | 2 | 2023 |
| Recombinant AAT-Fc fusion protein INBRX-101 achieves normal serum AAT levels in patients with alpha-1 antitrypsin deficiency (AATD) A Veale, H Farah, R Mahadeva, M Baker, B Kuhn, A Cole, C Chang, ... European Respiratory Journal 60 (suppl 66), 2022 | 2 | 2022 |
| Evaluation of Safety and Pharmacokinetics of the Recombinant Human AAT-Fc Fusion Protein INBRX-101 in Patients with Alpha-1 Antitrypsin Deficiency A Veale, J Kalabus, H Farah, R Mahadeva, BT Kuhn, A Cole, CL Chang, ... C41. ALPHA-1 ANTITRYPSIN DEFICIENCY, A4114-A4114, 2022 | 2 | 2022 |
| Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed … SK Agarwal, S Bhagwat, K Mehta, A Hindoyan, AS Stein, F Ravandi, ... Journal of Clinical Oncology 38 (15_suppl), 7536-7536, 2020 | 2 | 2020 |
| Recombinant Human Alpha-1 Antitrypsin (AAT) Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT … BT Kuhn, A Veale, H Farah, R Mahadeva, CL Chang, CD Brown, ... C15. EMERGING COPD DIAGNOSTICS AND TREATMENTS, A4492-A4492, 2023 | 1 | 2023 |
| Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers SS Bachhav, P Sheth, D Sandell, M Svensson, S Bhagwat, DS Conti, ... The AAPS journal 24 (1), 9, 2021 | 1 | 2021 |
| ACCURATE PREDICTION OF CLINICAL PHARMACOKINETICS OF THREE GENERATIONS OF BISPECIFIC T-CELL ENGAGERS (CANONICAL BITE CONSTRUCT; HALF-LIFE EXTENDED BITE CONSTRUCT; BISPECIFIC … V Upreti, M Yago, J Kast, D Zhou, H Wong, S Dhuria, S Agarwal, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S56-S56, 2021 | 1 | 2021 |
| Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject J Kalabus, S Bhagwat US Patent App. 18/318,425, 2023 | | 2023 |
| INBRX-101: A Novel Recombinant AAT-Fc Fusion Protein That Achieves Normal Serum AAT Levels with Extended Interval Dosing for Patients with Alpha-1 Antitrypsin Deficiency A Veale, J Kalabus, H Farah, R Mahadeva, BT Kuhn, A Cole, CL Chang, ... B14. OLD DOGS NEW TRICKS: LATE-BREAKING ABSTRACTS IN OBSTRUCTIVE LUNG …, 2022 | | 2022 |
| MECHANISTIC PK/PD MODELING IN SUPPORT OF A PATIENT-CONVENIENT, ONCE-WEEKLY DOSING REGIMEN OF KYPROLIS (CARFILZOMIB). M Yago, S Bhagwat, K Mehta, Z Klippel, M Obreja, V Chopra, S Dutta, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S73-S73, 2020 | | 2020 |
| 2017 Annual Meeting-What you need to know before you arrive J Ahn, S Albusaysi, J Alfonsi, A Ande, P Bank, E Barr, J Bezencon, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (3), 310-316, 2017 | | 2017 |
| Dissolution testing - Exploring the link between particle size and dissolution behavior for OINDPs Kippax P., Huck-Jones D., Suman J., Hochhaus G.,Bhagwat S. Drug Development and Delivery, 2016 | | 2016 |
| M1298 S Bhagwat, H Kranich, M Mueller, M Rohrschneider, A Goes, S Broenner, ... | | |
| Recombinant Human AAT Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT Deficiency BT Kuhn, A Veale, H Farah, R Mahadeva, CL Chang, CD Brown, ... History 2, 6.5, 0 | | |
